

Ref: FOIA Reference 2021/22-050

Royal Stoke University Hospital

Data, Security and Protection Newcastle Road Stoke-on-Trent Staffordshire ST4 6QG

Date: 18th May 2021

Email foi@uhnm.nhs.uk

Dear

I am writing to acknowledge receipt of your email dated 26th April 2021 requesting information under the Freedom of Information Act (2000) regarding oncology treatments

The University Hospitals of North Midlands Trust is committed to the Freedom of Information Act 2000.

However, the NHS is facing unprecedented challenges relating to the coronavirus (COVID-19) pandemic at the current time. Understandably, our resources have been diverted to support our front-line colleagues who are working tremendously hard to provide care for our patients, and to those in need of our services.

We strive to be transparent and to work with an open culture. But at this time, whilst care of our patients and the safety of our staff takes precedent, it is likely that responses to some requests for information will be delayed. We apologise for this position in advance, and will endeavour to provide you with as much information as we can, as soon as we are able.

The Information Commissioners Office has recognised the current situation in the NHS

I can neither confirm nor deny whether the information you have requested is held by the Trust in its entirety. This is because the information requested in questions part 2 and 3 is not held centrally, but may be recorded in individual health records. In order to confirm whether this information is held we would therefore have to individually access all individual health records within the Trust and extract the information where it is present. We therefore estimate that complying with your request is exempt under section 12 of the FOI Act: *cost of compliance is excessive*. The section 12 exemption applies when it is estimated a request will take in excess of 18 hours to complete. We estimate that accessing and reviewing all individual health records and then extracting relevant information would take longer than the 18 hours allowed for.

In addition to the section 12 exemption the Trust is also applying section 14 (1) exemption: *oppressive burden on the authority*

Under section 16 of the FOI Act we are required to provide requestors with advice and assistance where possible. We would therefore like to advise you that if your request is shortened to just the questions that we are able to comply within the 18 hour time frame. In order to avoid delay to your response we have provided this below.







As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 I have a Freedom of Information request regarding oncology treatments offered by your Trust. Could you please answer the following four questions?

- 1. How many patients were treated (for any condition) in the past 6 months with:
 - Abiraterone
 - Apalutamide
 - Cabazitaxel
 - Darolutamide
 - Docetaxel
 - Enzalutamide
 - Ruxolitinib

A1 See below:

- Abiraterone 60
- Apalutamide 0
- Cabazitaxel 15
- Darolutamide 5
- Docetaxel 146
- Enzalutamide 87
- Ruxolitinib 21

Q2 Please provide the total number of patients treated in the last 6 months for

- Myelofibrosis (ICD10 code D47.4)
- Myelofibrosis (ICD10 code D47.4) patients over the age 65
- Prostate cancer
- Metastatic prostate cancer
- A2 See below:
- Myelofibrosis (ICD10 code D47.4) = this information is exempt under section 21: *information reasonably accessible by other means*. This is because the information is available via the Trust's public website at the following link: <u>http://www.uhnm.nhs.uk/about-us/regulatory-information/freedom-of</u> <u>information-publication-scheme/freedom-of-information-disclosure-log/</u> As per our response to you on Reference 398-2021 14th December 2020
- Myelofibrosis (ICD10 code D47.4) patients over the age 65 = as above
- Prostate cancer = A total of 438 treatments took place at UHNM for patients diagnosed with prostate cancer over the period 01.10.2020 to 31.03.2021. 234 of these were first definitive treatments and 204 subsequent treatments
- Metastatic prostate cancer = we are unable to separate this from the figure above
- Q3 How many myelofibrosis (ICD10 code D47.4) patients has your Trust diagnosed in the past 3 years?







- Of these patients, how many were treated in the past 6 months with Hydroxyurea?
- Of these patients, how many have received no active treatment in the past 6 months?
- A3 Myelofibrosis (ICD10 code D47.4) = this information is exempt under section 21: *information reasonably accessible by other means*. This is because the information is available via the Trust's public website at the following link:

http://www.uhnm.nhs.uk/about-us/regulatory-information/freedom-of information-publicationscheme/freedom-of-information-disclosure-log/ As per our response to you on Reference 398-2021 14th December 2020

Of these patients, how many were treated in the past 6 months with Hydroxyurea? = 6 in total (diagnosis date not identified)

Q4 How many metastatic prostate cancer patients were treated in the past 6 months with:

Abiraterone

.

.

- Apalutamide
- Cabazitaxel
- Darolutamide
- Docetaxel
- Enzalutamide

A4 See below:

- Abiraterone 60
- Apalutamide 0
- Cabazitaxel 15
- Darolutamide 0
- Docetaxel 29
- Enzalutamide 87

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <u>http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx</u>







This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via <u>www.ico.org.uk</u>.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,

, Chert.

Jean Lehnert Data, Security & Protection Manager



